Prostate cancer Flashcards

1
Q

What does the prostate gland do

A

secretes fluid that nourishes and protects the sperm
during ejaculation prostate squeeces fluid into the urethra

• Prostate located below the bladder
- Connected to seminal vesicles
- The urethra passes through the prostate
• Prostate cancer only develops in men
• The vasa deferentia bring sperm from the testes to seminal vesicles. The seminal vesicles contribute fluid to semen during ejaculation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prostate gland - peripheral zone

A

the prostate gland is divided into several zones, peripheral zone is >70% of prostate tissue - largest contribution to normal function
also most common site of origin of prostate tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prostate enlargement

A

benign prostatic hyperplasia (another name)

common as men get older
if prostate gland gets too big it can block urine flow out of bladder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prostate cancer epidemiology

A

second most common cancer cause
leading cause of cancer associated death in men
risk increases with age
more common in caribbean and african men
less common in asian men
localised disease has 99% - 10 year survival if detected early

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prostate cancer diagnosis

A

 Prostate specific antigen (PSA) blood test.
- PSA exists in normal ranges in males (1-2 nanograms)
- High PSA = signs of prostate cancer
- Not the most accurate, as high levels of PSA can be triggered by other factors (e.g. exercise)
 Prostate examination (digital rectal examination-DRE).
- Can do further tests to confirm for prostate can if PSA levels are high
 MRI and ultrasounds scans.
- Only if the doctors find a lumpy mass
 Biopsies.
- Get sample to diagnose if something abnormal found in the scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Different types of prostate cancer

A

Acinar adenocarcinoma - develops in gland cells that line the prostate gland - most common cancer

ductal adenocarcinoma - starts in cells that line the ducts of prostate gland - spreads quicker and more lethal than acinar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prostate cancer metastasis

A

• As the disease progresses = metastasis in other sites
- Prostate is in the pelvic bone
- Pelvic bone metastasis = leads to spinal metastasis / bone metastasis
• The further metastasis has spread = less chance of survival
• Close metastasis = more common
• Further away metastasis = less common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Prostate cancer genetic alterations

A
  1. Fusion of ETS genes = transcription factor for erythrocytes (red blood cells)
  2. Tumour suppressor genes (PTEN or tp53) can be mutated / deleted
  3. Amplification / activation of MYC oncogene
  4. As we go to more severe metastatic disease = leads to amplifications of mutations of AR & BRCA genes (major role in prostate cancer)
    ar = androgen receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Prostate cancer STATUS

A

Localised prostate cancer - cancer completely inside prostate = has not spread and is treatable

Castrate-sensitive prostate cancer - cancer controlled by keeping testosterone level as low as if testicles were removed (castrate level)

cancer that stops growing if you control testosterone = chemical castration
as cancer progresses you get

castrate resistant prostate cancer - cancer growing even when testosterone leevels are below castrate level

hormone refractory prostate cancer - cancer no longer helped by any type of hormone therapy

hormone and cancer resistant are the same thing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the TNM stage

A

TNM = Tumour lymph node metastasises

0n = no tumour in lymph node
1n = tumour in lymph node
m0 = no metastasis
m1 = metastasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prostate cancer management

A

• Localised = usually want active surveillance / surgery to remove prostate gland
- Or you can have some radiation

• As the disease progresses (CSPC):

  • Can have hormone therapy to control testosterone levels, known as ADT
  • Or
  • You can have other hormonal drugs to help slow down disease progression when the cancer becomes metastatic

When you become CRPC = hormone therapy is not enough, can use other dugs e.g. localise radiation, doctaxel, PARPi etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

For localised disease - non pharmaceutical treatment options

A

 Active surveillance: PSA, DRE (digital rectal examination), imaging/biopsies (to see if the disease is stable).
- Monitor disease without treating it (done after a certain age e.g. 80+)

 Radiotherapy: (shrink the tumour)
external beam radiation (EBRT)
brachytherapy (internal radiation) – (nucleotides / seeds that slowly release radiation in the prostate gland).

 Radical prostatectomy: entire prostate gland plus tissue around it is removed (most common)
- So disease doesn’t come back & tissue removed so cancer doesn’t spread

 Pelvic lymph node dissection (PLND).
- Very close to prostate = prevents metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do androgens affect prostate cells

A

Androgens (testosterone) stimulate prostate cancer cells to grow
naturally produced by men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How can you reduce androgens? pharmacological treatment

A

androgen deprivation therapy

could remove testicles

lutenizing hormone-releasing hormone (LHRH) agonists/antagonists (basically hormone therapy)

When cancer becomes resistant to ^ then you use ARSI

ARSI - androgen receptor signalling inhibitor- prevent androgen function

examples of ARSI:
Abiraterone (inhibits synthesis of andorgens by inhibiting enzymes)

androgen receptor antagonists - enzalutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

LHRH vs ARSI

A

• LHRH antagonist = blocks luteinising hormone (LH)
- Therefore, no signal being produced = no testosterone production
• LHRH agonist = stimulates production of LH (LH causes testosterone production)
- Due to too much stimulation of LH = too much testosterone being produced = creates negative feedback loop
- = desensitisation of LH receptor = no LH effect on LH receptor (no testosterone produce)

• ARSI (abiraterone) = inhibits the production of Androgens by inhibiting CYP17 enzyme, that is involved in the production of (androgen) testosterone (enzymatic inhibition)
• AR receptor antagonist (ARA) e.g. Enzalutamide – blocks AR receptor
- Therefore, increase levels of testosterone won’t be able to bind in the AR receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

pharmacological treatments

once hormonal drugs dont work - Taxane

A

You can use TAXANES - mitototic inhibitors that stabilise microtubule assembly

• Taxanes in same group as vinkalkaloids
• Taxanes = work on microtubule structure
- Lead to a formation that is not effective (they stabilise microtubule instruction)
- Therefore, no mitosis & the cells will die
• Taxanes can act on AR receptor itself & inhibit anti-apoptotic proteins like BCL2
- (Anti-apoptotic proteins = prevent apoptosis)
- Therefore, increased apoptosis in cancerous tumour cells

17
Q

pharmacological treatments

once hormonal drugs don’t work - PARP

A

PARP are enzymes involved in damaged dna repair
PARP inhibitor block PARP enzymes

When you have 1 strand break = can lead to double strand break
• Double strand break needs to be repaired by homologous recombination
• When PARP is blocked by PARP inhibitor
- Cancers can sometimes have mutated BRACA gene
- Double-strand break needs to be repaired by homologous recombination by sister chromatids
- If you sister chromatid has BRACA mutation, then double strand DNA repair cannot happen
- PARP enzymes are inhibited, therefore, cannot have single strand repair = DNA repair cannot happen
- Cancer cell dies
• Use of PARP inhibitors in advance cancers, where BRACA is mutated

18
Q

Immunotherapies for cancer

A

Pembrolizumab - checkpoint inhibitor

Provenge - prostate cancer vaccine

19
Q

Pembrolizumab - anti PD1 antibody

checkpoint inhibitor

A

• Immunotherapies act by activating T-cell
• For the T cell to be activated, many things need to happen, because you do not want T cell to be overly activated & kill everything
• The T cell receptor will bind to the antigen & bind to the major histocompatibility complex (MHC) on APC (antigen presenting cells)
- For T cell to be activated you need co-activation of binding of CD28 & CD80/86
- You don’t want T cells to always be activated (cytotoxic cells)
• If you have the expression of PD1 (programmed cell death 1)
- That will bind to PDL1 (programmed death ligand 1), found on APC
- PDL1 / PD1 can be found on tumour cells
- Prescence of PD1 & PDL1 binding = blocks T cell activation
- Therefore, T cells cannot kill
• Cancerous cells can upregulate = PD1 binds to PDL1 receptor on T cells
- = prevents activation of T cells & cancerous cell does not die by T cell
• Pembrolizumab (anti- PD1 antibody) prevents PDL1 &PD1 receptor binding
- Therefore, T cell is activated & kills cancerous cells

20
Q

Provenge - prostatce cancer vaccine

A

• PAP = prostatic antigen phosphatase
• Take patients’ blood & try to collect white blood cells
- Want APC cells like dendritic cells (DCs) (process called leukapheresis)
• APCs incubated with PAP & they ingest PAP into small fragments called peptides
• APCs stimulated with GM-CSF (modulatory cytokine that activates APCs)
- provenge is infused into the patients vein
APCs express PAP & this is seen by T cells. Allowing them to bind to APC

 PAP (Prostatic acid phosphatase) is present in 95% of prostate cancer cells which is why we incubate it with APC
 granulocyte-macrophage colony stimulating factor (GM-CSF) also including to activate DCs

21
Q

How does provenge work?

A
  1. activated apcs in provenge present PAP peptides to T-cells
  2. T cells recognise PAP peptides as evidence of cancer and become activated
  3. activated T-cells recognised PAP peptides on surface of cancer cells and mount an attack

with this vaccine we train T cells to recognise what is cancer and what is not

22
Q

Summary

A

 Prostate cancer is a complex disease affecting millions of men.
 Key genetic alterations: ETS, MYC, PTEN, TP53, AR and BRCA.
 Treatment for localized disease: active surveillance, radical prostatectomy or radiotherapy.
 Treatment for advance disease (depending on castration status): ADT combined with
- ARSI
- Radiotherapy
- taxane-based chemotherapy
- PARPi
- immunotherapies